Open Source Health Announces Closing of Private Placement and Debt Settlement

All News from Open Source Health Investor News Press Releases

Toronto, Ontario, Canada – June 13, 2016: Open Source Health Inc. (CSE:OSH), (Frankfurt:0OS), a cloud based precision medicine platform that puts control into the hands of women to educate, advocate and collaborate on their own healthcare is pleased to announce that it has completed a private placement for gross proceeds of $170,000 (the “Offering”) through the issuance of 1,133,333 units (the “Units”) of the Company at a price of $0.15 per Unit. Each Unit is comprised of one common share (a “Common Share”) and one common share purchase warrant (a “Warrant“). Each Warrant entitles the holder thereof to acquire one additional Common Share of the Company exercisable for a period of 24 months from the closing of the Offering at an exercise price of $0.30 per Common Share.

In connection with the Offering, the Company has agreed to issue 250,000 Common Shares to RAMPartners S.A. (the “Agent”) for providing capital raising placement agent consulting services pursuant to a Capital Raising Placement Agent Agreement entered into between the Company and the Agent.

In addition, the Company also announces that it has agreed to settle an aggregate of $7,100.68 of indebtedness owed to an arm’s length creditor through the issuance of 47,338 common shares in the capital of the Company at a deemed price of $0.15 per common share.

All securities issued are subject to a hold period until October 7, 2016 pursuant to applicable securities laws.

 

About Open Source Health Inc.:

Open Source Health takes a truly patient-centered approach and is in the business of providing a cloud based, real-time precision medicine platform to Clinics and Practices that focus on Women’s Health. Open Source Health Inc. is leading the digital transformation of healthcare by leveraging the latest trends in digital health, precision medicine, molecular medicine, integrated and personalized health, social health and participatory medicine. This is medicine for the 21st century.

For more information, visit www.opensourcehealth.com

Contact:

For further information, please contact Investor Relations at Open Source Health Inc.
Toll Free: 1.866.403.1933 in North America

International Calling: +01.647.872.9986
http://www.opensourcehealth.com/contact-new/


 

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Open Source Health Inc. (“OSH”), including, but not limited to, the impact of general economic conditions, industry conditions and the uncertainty of obtaining additional financing. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

 

The forward-looking statements contained in this press release are made as of the date of this press release, and OSH does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Open Source Health announces launch of the first Women’s Precision Medicine Platform in Atlanta, USA

All News from Open Source Health Investor News Press Releases

Toronto, Ontario, Canada – June 9, 2016: Open Source Health Inc. (CSE:OSH), (Frankfurt:0OS), a cloud based precision medicine platform that puts control into the hands of women to educate, advocate and collaborate on their own healthcare is pleased to announce the launch of the myAva Precision Medicine Platform with it’s first cohort of women in Atlanta, GA.

“After 2 years of development we are finally set to deliver precision medicine to women with PCOS” says Sonya Satveit, CEO of Open Source Health Inc. “By providing an in-depth molecular insight of each woman, myAva will help achieve a new understanding of PCOS and has the potential to provide precision treatment programs customized to each woman’s unique molecular makeup.”

OSH has partnered with Medici Medial Arts – Center for Integrative Medicine and will work with their integrative healthcare team to deliver precision medicine to women in the Atlanta area.

The first use case for the myAva Precision Medicine platform is to support PCOS Precision Medicine by creating “digital version of each woman” based on her molecular makeup, biometric data, clinical evidence combined with the latest scientific knowledge. This digital version of each woman will contain molecular level information such as genetic information, blood proteins and metabolites, gut and vaginal microbiome, vital signs and biometric data collected from wearable technology (e.g., heart rate, activity levels, sleep patterns), self-reported data such as quality of life and environmental conditions. This data will be integrated and analyzed using computational biology approaches cross-referenced with the latest scientific and clinical findings to objectively characterize health status and to identify potential transitions from health to disease using various molecular metrics. Participants will receive regular analysis and consultation with a healthcare professional to interpret data and discuss options to maintain a healthy state and/or to match therapy to the particular disease state they may have or be trending towards. myAva will produce a personalized health dash board that highlights actionable items and tracks progress towards optimal health in real time.

The myAva platform will be offered to medical clinics that focus on women’s health on a “per patient” subscription basis. myAva will integrate into the current EHR (Electronic Health Record) systems in use by the clinic effectively adding precision medicine to the installed base of EHRs.

Additional revenue from product and service sales and a percentage of all provider billings through the system are also included in the revenue model. OSH estimates revenue in the $2,000.00 – $3,000.00 USD per patient annually. OSH expects each clinic will be able to support 3,000 to 5,000 PCOS patients annually using the myAva platform. There are 7 million women with PCOS in America today with global prevalence rates affecting from 10% – 20% of women. For example India is experiencing some of the highest prevalence rates today exceeding 20%.

OSH plans to add additional clinics later in 2016.

 

About Open Source Health Inc.:

Open Source Health takes a truly patient-centered approach and is in the business of providing a cloud based, real-time precision medicine platform to Clinics and Practices that focus on Women’s Health. Open Source Health Inc. is leading the digital transformation of healthcare by leveraging the latest trends in digital health, precision medicine, molecular medicine, integrated and personalized health, social health and participatory medicine. This is medicine for the 21st century.

For more information, visit www.opensourcehealth.com

Contact:

For further information, please contact Investor Relations at Open Source Health Inc.
Toll Free: 1.866.403.1933 in North America

International Calling: +01.647.872.9986
http://www.opensourcehealth.com/contact-new/

 

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Open Source Health Inc. (“OSH”), including, but not limited to, the impact of general economic conditions, industry conditions and the uncertainty of obtaining additional financing. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

The forward-looking statements contained in this press release are made as of the date of this press release, and OSH does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

OSH Announces Dr. Fiona McCulloch, Integrative Medicine & PCOS Expert to the Advisory Board

All News from Open Source Health Investor News Press Releases

Toronto, Ontario, Canada – June 2, 2016: Open Source Health Inc. (CSE:OSH), (Frankfurt:0OS), a cloud based precision medicine platform for women that puts control into the hands of women to educate, advocate and collaborate on their own healthcare is pleased to announce that Dr. Fiona McCulloch, has joined the advisory board of OSH.

“As one of North America’s top PCOS experts and as a woman with PCOS herself, Dr. Fiona McCulloch understands the impact of PCOS better than anyone,” says Sonya Satveit, CEO of Open Source Health Inc. “She is a well respected member of the large PCOS community and I couldn’t be more thrilled to have her join our team of Advisors.”

“By shining this bright light on PCOS, using precision medicine to inform each woman’s care with evidence-based integrative treatments, OSH is finally giving hope to the PCOS community,” states Dr. Fiona McCulloch, “This is the kind of attention the PCOS Community has been waiting for and I am so excited to be a part of it.”

As an expert member of our Advisory Board, Dr. Fiona McCulloch will help guide the development of our Precision Medicine PCOS Program. One of the most underserved of all women’s health issues globally, Polycystic Ovary Syndrome (PCOS) is the leading cause of infertility. PCOS affects approximately 10% of women in North America, yet half are undiagnosed. Approaching this complex syndrome at the molecular level will help us achieve a new understanding of PCOS and for the first time will deliver a personalized approach based on each woman’s individual circumstances.

OSH has granted Dr. McCulloch 100,000 stock options for her participation on the Advisory Board.

About Dr. Fiona McCulloch:

Dr. Fiona McCulloch’s clinical focus is on PCOS, Infertility, Gynecology, Autoimmune Disease and Thyroid Health. She has treated thousands of female and male patients for fertility concerns and has designed unique, groundbreaking natural fertility and IVF support programs. Dr. Fiona has a special interest in disorders of insulin resistance, and immune-endocrinology (the connection between the endocrine and immune systems).

Dr. Fiona has published several major articles in NDNR one of the leading journals for naturopathic doctors and other publications for health professionals. Her popular research-based blog receives a monthly readership of 30,000 per month. Dr. Fiona’s book on the treatment of Polycystic Ovary Syndrome – “8 Steps To Reverse Your PCOS” will be published on September 20th, 2016. Dr. Fiona is the Naturopathic Doctor advisor to IVF.ca Canada’s premier online fertility community. As a woman with PCOS herself, she is passionate about health education for women with this disorder, and holds a position on the medical advisory committee of the PCOS Awareness Association.

She lectures to naturopathic doctors and integrative medicine clinicians through various professional associations and to students at the Canadian College of Naturopathic Medicine on topics in her areas of expertise. As a strong proponent of evidence-based natural medicine, Dr. McCulloch peer-reviews for Natural Standard, an international research group affiliated with Harvard Medical School.

She is a member of The American Society for Reproductive Medicine, Ontario Association of Naturopathic Doctors, and the Canadian Association of Naturopathic Doctors. She is the only Naturopathic Doctor in Canada who is a member of The Fertile Soul and is part of a close network of specialized fertility practitioners including  Dr. Randine Lewis (Author of The Infertility Cure).

Dr. Fiona is a graduate of the Canadian College of Naturopathic Medicine (2001) and the University of Guelph (Biological Science). She is also a Registered Acupuncturist.

Clinical focus and special interests

As Founder of White Lotus Integrative Medicine Dr. Fiona has worked with thousands of people seeking better health over the past 15 years. She is committed to health education and advocacy, empowering her patients with the most current information on health topics and natural medicine therapies with a warm, empathic approach.

About Open Source Health Inc.:

Open Source Health takes a truly patient-centered approach and is in the business of providing a cloud based, real-time precision medicine platform to Clinic that focus on Women’s Health.. Open Source Health Inc. is leading the digital transformation of healthcare by leveraging the latest trends in digital health, precision medicine, molecular medicine, integrated and personalized health, social health and participatory medicine. This is medicine for the 21st century.

For more information, visit www.opensourcehealth.com

Contact:

For further information, please contact Investor Relations at Open Source Health Inc.
Toll Free: 1.866.403.1933 in North America

International Calling: +01.647.872.9986
http://www.opensourcehealth.com/contact-new/

 

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of Open Source Health Inc. (“OSH”), including, but not limited to, the impact of general economic conditions, industry conditions and the uncertainty of obtaining additional financing. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

The forward-looking statements contained in this press release are made as of the date of this press release, and OSH does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.